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Abstract Sendai virus expresses C protein that blocks inter-
feron (IFN) signaling. We previously reported suppression of
IFN-stimulated tyrosine phosphorylation of signal transducers
and activators of transcription (Stats) in infected cells. However
this conclusion has remained controversial. To settle it, we re-
examined the effect of C protein expression on phosphorylation
of Stat1 in detail. IFN-stimulated tyrosine phosphorylation of
Stat1 was doubtlessly suppressed early in infection, but the
suppression was incomplete, suggesting the importance of the
unknown blocking mechanism that inactivates the tyrosine-
phosphorylated (pY)-Stat1 generated as the signaling leak.
Interestingly, the dephosphorylation process of pY-Stat1 was
also impaired. These effects on both phosphorylation and
dephosphorylation processes were attributable to the function
of the C protein. ß 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
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1. Introduction
Interferons (IFNs) establish an antiviral state in cells by
inducing antiviral proteins such as double-stranded RNA-de-
pendent protein kinase, 2P^5P oligoadenyl synthetase and Mx
proteins [1^3]. Induction of the antiviral proteins results from
transcriptional activation of IFN-stimulated genes (ISGs) via
the IFN signaling pathway [1]. Binding of IFN-K/L to type I
IFN receptor causes tyrosine phosphorylation of receptor-as-
sociated ‘Janus’ tyrosine kinases (JAK family), Jak1 and
Tyk2. The activated JAKs tyrosine-phosphorylate the signal
transducer and activator of transcription (Stat) 2 and Stat1.
The tyrosine-phosphorylated (pY)-Stat2 and pY-Stat1 then
form a heterodimer, translocate into the nucleus and combine
IFN responsive factor 9 (p48) to form IFN-stimulated gene
factor 3 (ISGF3) and activate transcription of ISGs. On the
other hand, IFN-Q uses a similar but distinct pathway. Bind-
ing of IFN-Q to the type II IFN receptor facilitates transphos-
phorylation and activation of Jak1 and Jak2, which in turn
tyrosine-phosphorylate Stat1. The pY-Stat1 forms a homo-
dimer, termed IFN-Q-activated factor (GAF), translocates
into the nucleus and activates transcription of ISGs. Tran-
scriptional activation by GAF and ISGF3 requires co-factors
such as cyclic AMP response element binding protein binding
protein (CBP)/p300 to activate transcription of ISGs [4,5].
The pY-Stat1 is ultimately inactivated through dephosphory-
lation by a nuclear phosphatase [6,7]. Two forms of Stat1,
Stat1K and Stat1L, are present. Stat1L is translated from a
spliced form of Stat1K mRNA and lacks the COOH-terminal
31 amino acids of Stat1K [8,9]. This C-terminal region con-
tains the serine residue that is phosphorylated in response to
IFNs. The serine phosphorylation is required for maximal
transactivation function of GAF but not ISGF3 [10].
With the evolution of the host IFN system, viruses have co-
evolved mechanisms which antagonize the antiviral e¡ects of
IFNs [11^18]. The family Paramyxoviridae is not exceptional
as well [11]. The Paramyxoviridae contain important patho-
gens of children and infant, including human parain£uenza
viruses (hPIVs), mumps virus and measles virus. Recent stud-
ies revealed that members of the two genera, Rubulavirus and
Respirovirus, have evolved mechanisms that inhibit IFN sig-
naling [11]. Indeed, simian virus (SV) 5, SV41, hPIV2, and
mumps virus in the Rubulavirus inhibit IFN signaling by
decreasing the level of either Stat1 or Stat2 [19^28]. The
anti-IFN protein was found to be the V protein encoded by
the P gene [20,23^26]. On the other hand, Sendai virus (SeV)
in the other genus Respirovirus decreases none of the signal-
ing components in most cell lines except for NIH3T3 mouse
embryo ¢broblast cells [29^31]. Thus more extensive studies
are required to elucidate the underlying mechanism employed
by SeV.
SeV is an enveloped virus that possesses a single-stranded
negative-sense RNA genome which contains six tandemly
linked genes. Of six genes, the P gene is unique in giving
rise to a plethora of viral polypeptides including C and V
proteins by means of overlapping frames and by pseudotem-
plated nucleotide addition known as the RNA editing [32].
The C open reading frame (ORF) overlaps in the +1 frame
relative to the P ORF and produces a nested set of four C
proteins, CP, C, Y1 and Y2, referred to collectively as the C
proteins [33,34]. Initiation codons of CP, C, Y1 and Y2 are
81ACG, 114AUG, 183AUG and 201AUG, respectively. Trans-
lation of all the four C proteins terminates at the same posi-
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tion UAA728. Recent development in reverse genetic technol-
ogy succeeded in creating C knockout SeVs [35^38] and re-
vealed that the C gene is required for preventing the IFN
responses [30,39]. Although the importance of 114AUG initi-
ated C protein for blocking IFN signaling had been empha-
sized [39], studies using a series of knockout viruses including
four C knockout viruses [37,40] and using cells expressing
individual C protein demonstrated that not only C but also
Y1 and Y2 proteins have the capacity to inhibit the IFN
signaling pathway [30,31,41]. However, debate still continues
as to whether Y1 and Y2 proteins are able to rescue VSV
replication from the antiviral e¡ects of IFN [29,41].
Studies on the molecular mechanism by which SeV inter-
feres with IFN signaling have so far been analyzed on infected
cells [28,42,43]. The ¢rst important ¢nding is that tyrosine
phosphorylation of Stats in immediate response to IFN-K
was inhibited in the early phase of infection [42]. Young et
al., however, reported a distinct conclusion about this [28].
They suggested that SeV does not inhibit tyrosine phosphor-
ylation of Stat1 but does serine phosphorylation of Stat1 in
response to autocrine IFN induced by infection [28]. To re-
solve this discrepancy, we decided to examine more precisely
the e¡ect of SeV infection on phosphorylation of Stat1. We
show here that SeV suppresses de¢nitely tyrosine phosphory-
lation of Stat1 by short-time stimulation with IFN in the early
phase of infection. However, the suppression was incomplete.
The C protein contributed to not only the suppression of ty-
rosine phosphorylation but also the impairment of dephos-
phorylation of pY-Stat1. The present study thus emphasizes
the importance of another blocking mechanism, which inacti-
vates transcriptional activity of the pY-Stat1 generated as the
signaling leak.
2. Materials and methods
2.1. Cells and viruses
HeLa cells were maintained in Dulbecco’s minimum essential me-
dium (DMEM) supplemented with 10% fetal calf serum. A HeLa cell
clone, named C+, which constitutively expresses the C protein [41],
was grown in DMEM supplemented with 10% fetal calf serum and
100 Wg/ml blasticidin. The human cell lines, U118 [44] and HEC-1B
[45,46], were cultured in MEM supplemented with 10% fetal calf
serum, 0.1 mM non-essential amino acids and 1 mM sodium pyru-
vate. SeVpB, a temperature sensitive mutant [47], was propagated in
the allantoic cavity of 10-day-old embryonated eggs and was used for
most of experiments unless otherwise mentioned. Titers of SeVpB
were determined as described previously [48]. Recombinant SeVs,
wild-type (WT) (cDNA-derived Z strain) and 4C(3) [37,49], propa-
gated in Vero cells were titrated by the hemadsorption test as de-
scribed previously [30]. rSeV was used at the appropriate dilution so
that all cells were infected.
2.2. Chemicals and antibodies
Recombinant human IFN-K-2a and IFN-Q were purchased from
Takeda Chemical Industries, Osaka, Japan, and from RpD Systems
Inc., Minneapolis, MN, USA, respectively. Staurosporine was from
Wako Pure Chemical Industries, Ltd., Osaka, Japan. Anti-phospho-
(Tyr701) Stat1 (anti-pY-Stat1) rabbit polyclonal antibody (no. 9171)
was from New England Biolabs, Inc., Beverly, MA, USA. Anti-phos-
pho-(Ser727) Stat1 (anti-serine-phosphorylated (pS)-Stat1) rabbit poly-
clonal antibody (no. 06-802) was from Upstate Biotechnology, New
York, USA. Anti-Stat1 mouse monoclonal antibody SC-464 was from
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA. FITC-labeled
anti-rabbit IgG goat serum was from Tago, Burlingame, USA.
2.3. Western blot analysis
Cells were lysed with extraction bu¡er (50 mM HEPES, pH 7.6, 300
mM NaCl, 1% Triton X-100, 1 mM Na3VO4, 1 mM dithiothreitol,
1 mM phenylmethylsulfonyl £uoride, 1 Wg/ml leupeptin and 2 Wg/m
pepstatin) [50]. After centrifugation, the clari¢ed supernatant was
stored as the total extract at 380‡C. Total cell extracts (20^50 Wg
protein) were electrophoresed in 6% sodium dodecyl sulfate (SDS)^
polyacrylamide gels [51]. Proteins in the gels were transferred to nitro-
cellulose membranes (Bio-Rad, Richmond, CA, USA). Horseradish
peroxidase-conjugated goat anti-rabbit (Amersham Pharmacia Bio-
tech) was used as a secondary antibody. The proteins were detected
using ECL detection reagent (Amersham Pharmacia Biotech).
3. Results
3.1. IFN-independent tyrosine phosphorylation of Stat1 in
SeV-infected cells
Young et al. observed elevation of the pY-Stat1 level in
SeV-infected human diploid ¢broblast 2fTGH cells at 16 h
post-infection (pi) in the absence of exogenously added IFN
[28]. They interpreted this tyrosine phosphorylation as a result
of stimulation with autocrine IFN-K/L produced in response
to infection and concluded that SeV did not inhibit IFN-
stimulated tyrosine phosphorylation of Stat1. To con¢rm
the result, HeLa cells were infected with SeV and then har-
vested at 2 and 20 h pi. The levels of pY-Stat1 in the extracts
were estimated by Western blot analysis. Consistent with their
result, the pY-Stat1 level in HeLa cells obviously elevated at
20 h pi in the absence of exogenously added IFN (Fig. 1). To
determine whether this elevation is due to the response to
autocrine IFN-K/L, experiments were made in an IFN non-
responder cell line, HEC-1B [45,46], as well as in an IFN non-
producer cell line, U118 [44]. Interestingly, similar elevation
was observed in both cell lines (Fig. 1). These results revealed
that SeV infection per se could cause IFN-independent tyro-
sine phosphorylation of Stat1. It is therefore di⁄cult to de-
termine whether the elevation of the pY-Stat1 levels in in-
fected HeLa or 2fTGH cells in the absence of exogenously
added IFN was due to stimulation with autocrine IFN or
due to the IFN-independent tyrosine phosphorylation.
3.2. Leaky blockage in IFN-mediated tyrosine phosphorylation
of Stat1
Treatment of cells with IFN causes immediate tyrosine
phosphorylation of Stat1. We previously presented the data
Fig. 1. IFN-independent tyrosine phosphorylation of Stat1 in SeV-
infected cells. Con£uent monolayers of HeLa, U118 and HEC-1B
cells were infected with SeV at a multiplicity of infection of 10, and
harvested at indicated time points. Then the total cell extracts were
subjected to 6% SDS^PAGE followed by Western blot analysis with
anti-pY-Stat1 antibody. Results are representative of three inde-
pendent experiments.
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indicating that this process in response to either IFN-K or
IFN-Q was impaired at 2 h pi [42,43]. Suppression of IFN-
K-stimulated tyrosine phosphorylation of Stat1 was also ob-
served at 20 h pi, but the inhibitory e¡ect for IFN-Q stimula-
tion was abrogated by 20 h pi [43]. This conclusion was drawn
from estimation of the pY-Stat1 levels induced by short-time
(30 min) incubation with IFN at 2 h and 20 h pi.
To see more precisely the e¡ect of SeV infection on IFN-
stimulated phosphorylation of Stat1, we examined the level of
pY-Stat1 after continuous stimulation with IFN. Either IFN-
K or IFN-Q was added to the medium of infected or mock-
infected cells at 2 h pi and then incubated for the indicated
times (Fig. 2). Treatment of mock-infected cells with IFN-K
resulted in immediate increase in the intracellular level of pY-
Stat1, which reached a peak within 1 h and then decreased
from 2 h post-treatment (pt) (Fig. 2A, mock). The decrease in
the pY-Stat1 level is due to rapid dephosphorylation of pY-
Stat1 by a nuclear phosphatase [6,7]. When SeV-infected cells
were treated with IFN-K, the phosphorylation pattern strik-
ingly changed. The pY-Stat1 level retained nearly below the
detection level for 2 h after addition of IFN-K (Fig. 2B),
con¢rming the previous ¢nding [42]. Surprisingly, the level
of pY-Stat1 gradually increased from 4 h pt and reached a
peak at 12 h pt. Levels of pY-Stat1 are determined by the
balance of tyrosine phosphorylation and dephosphorylation
turnovers. On the other hand, SeV suppresses tyrosine phos-
phorylation caused by short-time stimulation with IFN-K in
not only early but also middle phases of infection [43]. There-
fore it is likely that the increase in the pY-Stat1 level from 4 h
pt resulted from accumulation of pY-Stat1 due to impairment
of the dephosphorylation process of the pY-Stat1 generated as
the signaling leak (see Section 3.4). A similar pattern was
observed for stimulation with IFN-Q (Fig. 2B), although the
phosphorylation levels were higher than those for stimulation
with IFN-K. In the absence of exogenously added IFNs, the
pattern was also similar although the phosphorylation level
was lower (Fig. 2C). Levels of Stat1 were not markedly af-
fected throughout infection (Fig. 2), demonstrating that the
early block was not due to degradation of Stat1. Stat1K was
detected as double bands at 8 and 12 h pt with IFN-Q in
infected cells (Fig. 2B). pY-Stat1 migrates slower than un-
phosphorylated Stat1 on SDS^polyacrylamide gel electropho-
resis (PAGE) [52]. Indeed the upper band migrated exactly at
the same position as the pY-Stat1K did, indicating that a large
proportion of Stat1 was tyrosine-phosphorylated at 8 h or 12
h pt with IFN-Q in infected cells. From these results we con-
cluded that SeV suppresses tyrosine phosphorylation in imme-
diate response to either IFN-K or IFN-Q in the early phase of
infection but the suppression was incomplete. It is unclear
why the levels of pY-Stat1 decreased in infected cells at 24
and 48 h pt, compared with those at 8 and 12 h pt. It is,
however, evident that the decrease did not correlate with
changes of the Stat1 levels (Fig. 2).
3.3. E¡ect of SeV infection on serine phosphorylation of Stat1
Young et al. reported that the intracellular level of pS-Stat1
was below the detection level at 16 h pi in infected cells in the
absence of exogenously added IFNs [28], suggesting that SeV
inhibits autocrine IFN-K/L-stimulated serine phosphorylation
of Stat1. To con¢rm their result, we also examined the e¡ect
of SeV infection on serine phosphorylation of Stat1 using the
Fig. 2. E¡ect of SeV infection on tyrosine phosphorylation of Stat1
in response to continuous stimulation with IFN. HeLa cells were
mock-infected or infected with SeV 2 h before addition of IFN-K
(1000 U/ml) (A) or IFN-Q (500 U/ml) (B), or mock treatment (C).
Cells were harvested at indicated time points after addition of IFN.
The total extracts were subjected to 6% SDS^PAGE followed by
Western blot analysis with anti-pY-Stat1 or anti-Stat1 antibody. Re-
sults for A^C are representative of three independent experiments.
Fig. 3. E¡ect of SeV infection on serine phosphorylation of Stat1 in
response to continuous stimulation with IFN. Experimental condi-
tions were the same as those described in Fig. 2. The total extracts
were subjected to 6% SDS^PAGE followed by Western blot analysis
with anti-pS-Stat1 antibody. Results for A^C are representative of
three independent experiments.
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same samples that were analyzed in Fig. 2 (Fig. 3). Treatment
of mock-infected cells with IFN-K resulted in a more gradual
increase in the level of pS-Stat1 (Fig. 3A), compared with that
in the pY-Stat1 level (Fig. 2A). In contrast, no serine phos-
phorylation was observed at any incubation periods in in-
fected cells irrespective of the presence of exogenously added
IFN-K (Fig. 3A,C), demonstrating that SeV suppresses serine
phosphorylation in response to either IFN-K or autocrine
IFN. Since serine phosphorylation of Stat1 is not required
for the transcriptional activity of ISGF3, this suppression
never contributes to the inhibition of IFN signaling. Treat-
ment of mock-infected cells with IFN-Q exhibited a similar
pattern to the case of stimulation with IFN-K (Fig. 3B). In
SeV-infected cells, the level of pS-Stat1 increased from 6 h pt,
reached a peak at 8 h pt and returned to the basal level by 48
h pt. As a whole, a suppressive e¡ect of SeV infection on IFN-
Q-mediated serine phosphorylation was observed, but the lev-
els of pS-Stat1 at 6 and 8 h pt were comparable to those in
mock-infected cells (Fig. 3B). Since the pS-Stat1 band ob-
served at 6 and 8 h pt migrated at the same position as the
pY-Stat1 band did (data not shown), they are doubly phos-
phorylated at the tyrosine and serine residues. Thus these
e¡ects of SeV infection on serine phosphorylation of Stat1
never account for the inhibition of IFN signaling.
3.4. The C protein is responsible for the suppression of tyrosine
phosphorylation of Stat1 as well as the accumulation of
pY-Stat1
To determine whether the e¡ect on tyrosine phosphoryla-
tion of Stat1 is attributable to the function of the C protein,
we examined the e¡ect of infection with the C knockout SeV,
4C(3) virus, which does not express any of four C proteins,
on IFN-stimulated tyrosine phosphorylation of Stat1. Cells
were infected with WT or 4C(3) virus and then incubated
with IFN-K or IFN-Q for 1 or 20 h. As shown in Fig. 4A,
Stat1 was tyrosine-phosphorylated in response to either IFN-
K or IFN-Q in 4C(3)-infected cells (Fig. 4A, lanes 3 and 5).
Notable elevation of pY-Stat1 levels was observed for 20 h
incubation in WT-infected cells, whereas no pY-Stat1 accu-
mulated in 4C(3) virus-infected cells (Fig. 4A, lanes 2, 4 and
6). These results demonstrated that the C protein was required
for the suppression of tyrosine phosphorylation of Stat1 in
response to short-time stimulation with IFN as well as the
accumulation of pY-Stat1 caused by continuous IFN stimu-
lation. The C+ cells constitutively expressing the SeV C pro-
tein display unresponsiveness to IFNs comparable to SeV-in-
fected cells [41]. C+ cells were treated with IFN-K or IFN-Q
Fig. 4. The C protein is responsible for the inhibitory e¡ects on ty-
rosine phosphorylation of Stat1 as well as the accumulation of pY-
Stat1. In A, HeLa cells were mock-infected or infected with either
WT or 4C(3) virus. Then either IFN-K (1000 U/ml) or IFN-Q (500
U/ml) was added to the media at 2 h pi. The cells were harvested at
1 h and 20 h after addition of IFN. In B, HeLa or C+ cells were
treated with IFN-K (1000 U/ml) or IFN-Q (500 U/ml) and harvested
at indicated times. The total cell extracts were subjected to 6%
SDS^PAGE followed by Western blot analysis with anti-pY-Stat1
antibody. Results for A and B are representative of three indepen-
dent experiments.
Fig. 5. Impairment of the dephosphorylation process of pY-Stat1 by
the C protein. HeLa cells were mock-infected (A) or infected with
SeV (B), and then treated with IFN-Q at 2 h pi for 1 h or 20 h, re-
spectively. C+ cells (C) were treated with IFN-Q for 20 h. Then the
cells (A^C) were mock-treated (3) or treated with staurosporine
(500 nM) (+) for indicated times. The total cell extracts were ana-
lyzed by 6% SDS^PAGE followed by Western blot analysis with
anti-pY-Stat1 antibody. Results for A^C are representative of three
independent experiments.
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for 1 or 20 h. Immediate response to IFN-K (Fig. 4B, lane 3)
but not IFN-Q (Fig. 4B, lane 5) was suppressed in C+ cells.
This result was in good agreement with the inhibition pattern
previously observed in the middle phase of infection [43].
Continuous stimulation of C+ cells with either IFN-K or
IFN-Q resulted in obvious elevation of pY-Stat1 levels (Fig.
4B, lanes 4 and 6). Neither virus infection nor expression of
the C protein decreased the levels of Stat1 (data not shown).
These results demonstrated that the e¡ects of SeV infection on
phosphorylation of Stat1 were attributable to the function of
the C protein. Interestingly, the very low level of pY-Stat1
was detected in C+ cells without any treatment (Fig. 4B, lanes
1 and 2). Thus the C protein may be responsible in part for
the elevation of pY-Stat1 in SeV-infected U118 or HEC-1B
cells.
3.5. Impairment of the dephosphorylation process of pY-Stat1
Staurosporine, known as a powerful kinase inhibitor, was
used to determine whether the dephosphorylation process was
impaired in infected cells or C+ cells. Since staurosporine
inhibits phosphorylation of Stat1, the dephosphorylation pro-
cess of pY-Stat1 would consequently become visible [6]. When
the pY-Stat1 level in mock-infected cells reached a peak by
treatment with IFN-Q for 1 h (Fig. 5A, lane 1), staurosporine
was added to the media. As shown in Fig. 5A, the pY-Stat1
level decreased immediately after addition of staurosporine
and almost disappeared within 60 min (Fig. 5A, lanes 2^4),
indicating prompt inactivation of pY-Stat1 through dephos-
phorylation by the nuclear phosphatase. Treatment of cells
with staurosporine did not a¡ect the level of Stat1 (data not
shown). In contrast, the level of pY-Stat1 generated in in-
fected HeLa cells or C+ cells by continuous stimulation
with IFN-Q (Fig. 5B,C) or IFN-K (data not shown) was main-
tained even in the presence of staurosporine. These results
suggested that the C protein impaired the dephosphorylation
process of pY-Stat1.
3.6. The C protein never impaired translocation of pY-Stat1
into the nucleus
The dephosphorylation process of pY-Stat1 takes place in
the nucleus [6]. To exclude the possibility that the impairment
of the dephosphorylation process is due to a block in the
translocation of Stat1 into the nucleus, the immuno£uorescent
staining experiment was performed using anti-pY-Stat1 anti-
body. There was little £uorescence without IFN treatment
(Fig. 6a,c), while obvious £uorescence in the nucleus was de-
tected in both mock-infected (Fig. 6b) and infected cells (Fig.
6d) with IFN-Q treatment, indicating that upon IFN-Q stimu-
lation pY-Stat1 translocated into the nucleus even in the pres-
ence of the C protein.
4. Discussion
The present study showed that continuous stimulation of
infected cells with IFN-K or IFN-Q resulted in generation of a
considerable amount of pY-Stat1. Under this condition, pY-
Stat1 generated by IFN-Q stimulation was doubly phosphor-
ylated on both serine and tyrosine. Since infected cells are
unresponsive even to continuous IFN stimulation, these re-
sults strongly suggest the presence of the second blocking
mechanism that inactivates the leak pY-Stat1. These e¡ects
on phosphorylation were attributable to the functions of the
C protein. The second mechanism is thought to be indispens-
able for the block in IFN signaling. If so, does the suppression
of tyrosine phosphorylation of Stat1 observed in the early
phase of infection contribute to the inhibition of IFN signal-
ing? Since the amount of the C protein is very low early in
infection (2 h pi), the second blocking mechanism may not
have been established in this early phase. It is therefore pos-
sible that in the context of infection the suppression of tyro-
sine phosphorylation plays a critical role until the second
blocking mechanism has been established.
The C protein impaired the dephosphorylation process of
the leak pY-Stat1. The role of this impairment in the signaling
block remains to be elucidated. The C protein physically as-
sociates with both unphosphorylated Stat1 and pY-Stat1 [43].
Therefore the C-Stat1 association may contribute to the im-
pairment of the dephosphorylation process, although the pos-
sibility cannot be excluded that the C protein directly inhibits
the function of the nuclear phosphatase. N-terminal mutants
of Stat1 impair the dephosphorylation process, suggesting
that the N-terminal region a¡ects phosphatase access [53].
On the other hand, Stat1 interacts with CBP/p300 through
two separate regions, N-terminal and C-terminal regions, of
Stat1. Thus the C protein may prevent factors such as the
nuclear phosphatase and CBP/p300 from being accessible to
Stat1 through interaction with domains nearby the N-terminal
region of Stat1. The analysis on the interacting domains of the
C protein and Stat1 is now in progress.
How does the C protein suppress IFN-stimulated tyrosine
phosphorylation of Stats? The C protein may be also respon-
sible for the e¡ects of SeV infection on IFN-mediated serine
phosphorylation of Stat1, because the phosphorylation pat-
terns observed in 4C(3) virus-infected cells and in C+ cells
were similar to those in mock-infected cells and in SeV-in-
fected cells, respectively (data not shown). There may be a
Fig. 6. Translocation of pY-Stat1 into the nucleus in infected cells.
Con£uent monolayers of HeLa cells were mock-infected (a, b) or in-
fected with SeV (c, d). At 20 h pi, the cells were then mock-treated
(a, c) or treated with IFN-Q for 30 min (b, d). The cells were ¢xed,
permeabilized and then subjected to immuno£uorescent staining
with anti-pY-Stat1 antibody according to the manufacturer’s in-
structions. Results for a^d are representative of two independent ex-
periments.
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common underlying mechanism between them. Tyrosine
phosphorylation of Stat2 and Stat3 in addition to Stat1 is
suppressed in response to IFN-K in the early phase of infec-
tion as described previously [42]. Activation of Tyk2 was par-
tially impaired in this phase [42]. Thus it is possible that the
C protein acts at the JAK or receptor level. Interestingly, in the
middle phase of infection, tyrosine phosphorylation of JAKs
in response to either IFN-K or IFN-Q was inhibited (unpub-
lished results), although Stat1 was e⁄ciently tyrosine-phos-
phorylated in response to IFN-Q stimulation, suggesting the
presence of JAK-independent tyrosine phosphorylation in re-
sponse to IFN-Q in infected cells. The molecular basis for this
mechanism may be linked to that for the blocking mechanism
that suppresses IFN-stimulated tyrosine phosphorylation of
Stat1.
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